OVID THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 USD | +3.68% |
|
-4.02% | -3.73% |
| Mar. 08 | Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 08 | Earnings Flash (OVID) OVID THERAPEUTICS Reports Q4 Revenue $141,562 | MT |
Presenter SpeechJeremy Levin (Executives)Hello, everybody. Thank you for joining us today. Thi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.1
USD
Average target price
7.167
USD
Spread / Average Target
+131.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.73% | 220M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Transcript : Ovid Therapeutics Inc. - Special Call
